drugset / Trial / NCT03220776

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776

RandomizedCrossoverQuadruple-blindBasic science

Summary

The proposed 3-week, double-blind, crossover, proof of concept study aims to manipulate neurochemical dysfunctions characteristic of individuals with co-occurring BD and AUD (i.e., abnormally low prefrontal GABA and glutamate), using medications that have been shown to normalize cortical GABA (i.e., gabapentin) and glutamate (i.e., NAC) levels in past research, and to evaluate medication-related changes in response inhibition and alcohol cue-reactivity fMRI tasks as well as drinking and mood in individuals with AUD+BD.

Timeline

Start
2017-08-07
Primary completion
2022-11-21
Completion
2022-11-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 1200 mg
Subject N-acetylcysteine Small molecule 2400 mg